Alembic Pharma

Alembic Pharma secures final USFDA approval for Dexlansoprazole DR capsules

Alembic Pharma shares rally sharply over 6% as Q2 net profit jumps 21% YoY to Rs 185 crore, revenue up 16%

Alembic Pharma Q2 Results: Revenue jumps 16% YoY to Rs 1,910 crore, net profit up 21%

Alembic Pharma receives USFDA final approval for Phytonadione Injectable Emulsion USP

Alembic Pharma gets USFDA nod for Carbamazepine Extended-Release Tablets

Alembic Pharma acquires UK-based Utility Therapeutics for $12 million to expand US presence

Alembic Pharma share jump 11% after company gets US FDA approval for Doxorubicin Hydrochloride Injection

Alembic Pharma receives EIR from USFDA for Karakhadi API-III facility

Alembic Pharma shares dip over 2% after USFDA issues 4 observations for Panelav facility

Alembic Pharma share price jumps 3% after USFDA issues EIR from for Panelav plant

Alembic Pharma shares drop 2.6% after US FDA issues one observation for Vadodara unit

Alembic Pharma Q2 FY25 Results: Revenue jumps 3.3% YoY to ₹1,647.98 crore, net profit jumps 12.2% YoY

Alembic Pharmaceuticals receives USFDA final approval for Lamotrigine Extended-Release Tablets

Stocks To Watch Today: Sun Pharma, Alembic Pharma, BEL, Crompton Greaves, and Campus Activewear

Top stocks to watch are Sun Pharma, Alembic Pharma, BEL, Crompton Greaves, and Campus Activewear, besides others.

Alembic Pharma receives USFDA approval for Fulvestrant Injection